Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

KTTA

Pasithea Therapeutics Corp

Dec 11 • 04:00PM ET

2.75

Dollar change -0.19
Percentage change -6.46	%

Healthcare • Biotechnology • USA • NASD

Peers: CMPS MNMD ATAI CYBN GHRS RLMD PALI SLS WKSP

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-15.13	Insider Own	19.08%	Shs Outstand	1.04M	Perf Week	-5.50%
Market Cap	3.48M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.02M	Perf Month	-16.67%
Income	-15.78M	PEG	-	EPS next Q	-	Inst Own	9.87%	Short Float	2.37%	Perf Quarter	-30.29%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.03	Perf Half Y	-52.39%
Book/sh	17.05	P/B	0.16	EPS next Y	-	ROA	-63.93%	Short Interest	0.02M	Perf Year	-61.16%
Cash/sh	7.40	P/C	0.37	EPS next 5Y	-	ROE	-68.24%	52W Range	2.80 - 17.40	Perf YTD	-62.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-88.56%	52W High	-84.20%	Beta	0.73
Dividend TTM	-	Quick Ratio	14.81	Sales past 5Y	-33.33%	Gross Margin	-	52W Low	-1.79%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	14.81	EPS Y/Y TTM	-22.05%	Oper. Margin	-	RSI (14)	34.49	Volatility	8.55% 8.10%
Employees	8	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	40.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-0.05%	Payout	-	Rel Volume	0.02	Prev Close	2.94
Sales Surprise	-33.33%	EPS Surprise	-5.88%	Sales Q/Q	-	Earnings	-	Avg Volume	948.88K	Price	2.75
SMA20	-10.07%	SMA50	-26.25%	SMA200	-49.29%	Trades		Volume	20,070	Change	-6.46%

Nov-20-24 07:02AM	Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire)
Sep-26-24 06:44PM	Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +52.15%
07:02AM	Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire)
Sep-09-24 08:01AM	Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies (GlobeNewswire)
Sep-03-24 08:02AM	Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board (GlobeNewswire) +6.57%
09:11AM	Loading…
Aug-28-24 09:11AM	Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Jun-25-24 12:52PM	KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023 (InvestorPlace) +6.64%
Jun-13-24 06:59AM	Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial (GlobeNewswire)
May-28-24 06:59AM	Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting (GlobeNewswire)
May-15-24 09:53AM	KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-29-24 07:59AM	Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-24-24 07:59AM	Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers (GlobeNewswire)
Apr-15-24 11:00AM	11 Undervalued Stocks for Less Than $50 in April 2024 (Investopedia)
Feb-13-24 07:59AM	Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 (GlobeNewswire) +8.95%
Jan-08-24 07:59AM	Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position (GlobeNewswire) +5.03%
08:35AM	Loading…
Jan-02-24 08:35AM	Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients (GlobeNewswire) +8.78%
Dec-28-23 05:00PM	Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 (GlobeNewswire) -5.13%
Dec-19-23 05:19PM	Pasithea Therapeutics Announces Results from 2023 Annual Meeting (GlobeNewswire) -6.06% -13.61%
Dec-13-23 09:03AM	Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today? (InvestorPlace)
Dec-11-23 11:18AM	Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today? (InvestorPlace) +47.42%
08:01AM	Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models (GlobeNewswire)
Nov-29-23 04:27PM	Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders (GlobeNewswire) +6.63% -7.91%
07:59AM	Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development (GlobeNewswire)
Nov-09-23 07:59AM	Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets 5 1 Integrin for the Treatment of both Sporadic and Familial ALS (GlobeNewswire)
Sep-14-23 08:30AM	Pasithea Therapeutics Corp. Announces Final Results of Tender Offer (GlobeNewswire)
Sep-07-23 04:14PM	Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -13.18%
Aug-01-23 07:59AM	Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in 5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting 5 integrin results in improved survival and motor function (GlobeNewswire)
Jul-31-23 06:00AM	The Psychedelics Stock Universe Is Shrinking, Despite the Hype (Bloomberg)
Jul-20-23 08:43AM	Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash (GlobeNewswire) +25.88%
08:40AM	Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc. (GlobeNewswire)
09:14AM	Loading…
Jul-13-23 09:14AM	Lucy Scientific Scores Richard Nanula as CEO After Senior Roles at Disney, Amgen, Starwood (Exec Edge)
Jun-30-23 09:28AM	Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors (GlobeNewswire)
Jun-29-23 02:50PM	Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp. (GlobeNewswire) +11.24%
08:29AM	Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004 (GlobeNewswire)
Jun-06-23 04:30PM	Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc. (GlobeNewswire)
Jun-05-23 09:00AM	Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp. (GlobeNewswire) +25.00%
Jun-01-23 07:57AM	Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference (GlobeNewswire)
May-14-23 08:13AM	Pasithea Therapeutics First Quarter 2023 Earnings: US$0.13 loss per share (vs US$0.068 loss in 1Q 2022) (Simply Wall St.)
May-03-23 08:26AM	Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference (GlobeNewswire)
Mar-02-23 08:00AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting (GlobeNewswire)
Feb-23-23 08:00AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) (GlobeNewswire) -5.64%
Feb-16-23 07:30AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award (GlobeNewswire)
Jan-18-23 08:00AM	Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004 (GlobeNewswire)
Dec-14-22 05:18PM	Majority of Stockholders Support Pasithea Directors at Special Meeting (GlobeNewswire)
Dec-12-22 07:00AM	Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group (GlobeNewswire) -8.22%
Dec-07-22 04:00PM	Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics (Business Wire)
Dec-06-22 08:00AM	Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference (GlobeNewswire)
Nov-28-22 07:05PM	Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time (GlobeNewswire)
Nov-22-22 04:00PM	Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics (Business Wire)
Oct-27-22 09:50AM	A New BioTech Research Race Is Focused On Improving Life For MS Patients (News Direct)
Oct-17-22 08:00AM	Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium (GlobeNewswire) -11.20%
Oct-14-22 09:48AM	Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive (Benzinga)
Oct-13-22 04:00PM	Investor Group Comments on Pasithea Therapeutics Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics (Business Wire)
Oct-12-22 08:00AM	Pasithea Therapeutics Acquires AlloMek Therapeutics (GlobeNewswire)
07:31AM	EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition (Benzinga)
Oct-10-22 09:39AM	New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope (News Direct)
Oct-03-22 06:03PM	Pasithea Therapeutics to Call Special Meeting of Stockholders (GlobeNewswire)
09:09AM	Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis (News Direct)
Sep-28-22 09:00AM	Investor Group Sends Letter to Pasithea Therapeutics Board of Directors (Business Wire)
Sep-20-22 08:00AM	Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors (GlobeNewswire)
Sep-15-22 08:00AM	Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz (GlobeNewswire)
Sep-12-22 11:53AM	Here's Why We're Not Too Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation (Simply Wall St.)
Sep-09-22 10:32AM	Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-06-22 09:30AM	Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics (Business Wire)
Aug-24-22 08:00AM	Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting (Business Wire)
Aug-18-22 08:00AM	Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference (GlobeNewswire)
Aug-11-22 08:00AM	Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis (GlobeNewswire) +6.83%
07:30AM	EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox (Benzinga)
Aug-05-22 09:00AM	Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting (Business Wire)
Aug-02-22 07:00AM	Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Groups Unjustified Campaign (GlobeNewswire)
Jul-14-22 08:00AM	Pasithea Therapeutics Awarded a Drug Development Research Grant (GlobeNewswire)
Jun-23-22 09:00AM	Investor Group Comments on Pasithea Therapeutics Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5 (Business Wire)
08:00AM	Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond (GlobeNewswire)
Jun-22-22 08:00AM	Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC (GlobeNewswire)
07:30AM	EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition (Benzinga)
Apr-14-22 04:15PM	Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022 (GlobeNewswire) +9.76% -8.89%
Apr-05-22 03:57PM	We're Not Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn (Simply Wall St.)
Mar-30-22 04:15PM	Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022 (GlobeNewswire) -7.14%
Mar-08-22 08:00AM	Pasithea Therapeutics Announces Collaboration with The Glimpse Group (GlobeNewswire) +7.08%
07:30AM	EXCLUSIVE: Glimpse-Pasithea To Co-Develop VR Environments For Patients With Psychiatric Disorders (Benzinga)
Feb-24-22 08:00AM	Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022 (GlobeNewswire)
Feb-09-22 08:00AM	Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger (GlobeNewswire)
Feb-03-22 08:00AM	Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis (GlobeNewswire) -6.40%
Jan-26-22 08:00AM	Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments (GlobeNewswire)
Dec-23-21 11:35AM	KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today (InvestorPlace) +36.73%
07:36AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Dec-21-21 08:00AM	Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom (GlobeNewswire) +9.72%
Dec-01-21 08:00AM	Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada (GlobeNewswire) -8.59%
Nov-29-21 05:45PM	Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules (GlobeNewswire) +5.99% -15.06%
Nov-24-21 08:52AM	Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules (GlobeNewswire) -28.75%
07:34AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Nov-23-21 11:39AM	5 Top Stock Gainers for Tuesday Climb After Powell Renomination (TheStreet.com) +153.39%
11:31AM	KTTA Stock: The Depression Nasal Spray News That Has Pasithea Therapeutics Investors Ecstatic Today (InvestorPlace)
08:00AM	Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K. (GlobeNewswire)
05:02AM	Pasithea Therapeutics Stock Skyrockets On Nasal Spray Approval (Investing.com)
Nov-17-21 08:00AM	Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint (GlobeNewswire) -5.18%
07:30AM	EXCLUSIVE: Pasithea Clinics Launches In-Home Intravenous Ketamine Therapy In Major US Cities (Benzinga)
Nov-11-21 08:00AM	Pasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine Therapy (GlobeNewswire)
Nov-09-21 08:00AM	Pasithea Therapeutics Corp. Establishes Scientific Advisory Board and Names Dr. Charles B. Nemeroff as Chair (GlobeNewswire)
Oct-27-21 11:40AM	Biotech Companies Are Embracing the Growing Psychedelic Drug Market To Confront a Global Increase in Depression and Anxiety (Benzinga) +9.23%

Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Steinman Lawrence J in May, 2020 and is headquartered in Miami Beach, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KTTA

Pasithea Therapeutics Corp

Upgrade your FINVIZ experience